Primary cutaneous leiomyosarcoma (PCL) are soft-tissue sarcoma, arising in the dermis, with or without extension into the subcutis. They are thought to have an indolent course compared to their subcutaneous counterparts, they may recur but rarely metastases. We report the case of a patient with a PCL arising in the anterior trunk wall who developed pulmonary, bone and retroperitoneal metastases 6 years after wide surgical excision of the primary tumor.
Primary cutaneous leiomyosarcoma (PCL) are the rarest subtype, arising in the dermis, with or without extension into the subcutis.
They are thought to have an indolent course compared to their subcutaneous counterparts; they may recur but rarely metastases.
We report the case of a patient with a PCL arising in the anterior trunk wall who developed pulmonary, bone and retroperitoneal metastases 6 years after wide surgical excision of the primary tumor. 
Patient and observation

Discussion
Primary Cutaneous Leiomyosarcomas (PCL) are highly-infrequent mesechymatal malignant neoplasm which are thought to arise from the arrector pili muscles in the dermis. They were described for the first time in 1959 by Montgomery and Winkleman [1] . Histogenesis remains unclear but physical trauma, radiation exposure and medical history of leiomyoma are suspected to be the most predisposing factor [1] . Association with burn and small pox scars was reported too [2, 3] . PCL mainly affects patients in the 5 th and 6 th decade of life with a male preference [4] [5] [6] . Some pediatric cases have been reported in literature [7] . Our patient was 30-year-old.
PCL may arise in any part of the body but preferentially involve the extremities, particularly hair bearing areas [4] [5] [6] . Localization to the trunk as seen in our case is of a rare occurrence [8] [9] [10] . Clinically, patients typically present with a slow-growing solitary nodule with an indolent growth pattern [10, 11] . Overlying skin can be normal or erythematous. The size range is often between 0.3-5cm [11] .
Pain and sudden accelerated growth are the most warning signs for which patients seek medical attention. Pruritis, ulceration and bleeding were reported too.
As clinical presentation may be non-specific, the diagnosis is on the basis of the histologic findings and immunohistochemical examination. It is usually made upon a skin biopsy. However, benign findings should not exclude the possibility of a cutaneous leiomyosarcoma [12] . In our report, the diagnosis of leiomyoma was first rendered and surgical removal was the surest way to establish a definite diagnosis. The dermal variant of leiomyosarcoma is rare and the pathologist must be very careful in assessing depth of invasion. PCL is generally confined to the skin but can exhibit focal and superficial extension into subcutis as seen in our case.
At present, there are no consensuses concerning the optimal treatment of PCL. Although there is evidence that wide local excision with negative lateral margins and depth including the subcutaneous tissue and fascia is the mainstay of treatment, the optimal excision margins for PCL remains controversial. As the recurrence rate and metastatic risk of PCL are strongly related to the adequacy of surgery, a large excision that includes 3-5 cm of uninvolved margins is strongly recommended [13, 14] . Otherwise, evidence from several clinical studies has supported a minimum surgical margin of 1cm [4] . Mohs micrographic surgery is also an attractive option to successfully treat PCL [15] . Although surgery remains the only curative treatment, radiation therapy was reserved to some cases considered to be at higher risk of recurrence. The factors taken into account were tumors larger than 5cm, high mitotic rate, positive surgical margins and subcutaneous extension of the dermal tumor [4, 16, 17] . Other prognostic factor predicting how aggressive the disease course will be were reported too: high mitotic rate of > 20 per 10 high-power fields (HPF), lesions greater than 5cm, tumor necrosis of > 50%, vascular invasion, increased tumor depth with fascial involvement, high stage, increased DNA ploidy, high Ki-67 proliferative index and acral distribution [5, 6] .
Although our patient has shown numerous factors of bad prognosis including tumor size, subcutaneous involvement and numerous atypical mitotic figures, he didn't undergo re-excision to obtain wider margins or receive adjuvant therapy. That may be partly due to the presumed benign course of PCL and no standardized treatment regimens. To date, effectiveness of radiotherapy in this setting has not been determined especially that it has been considered as a causative factor itself. Reports have shown that both radiotherapy and chemotherapy should be reserved for cases of recurrence or metastasis [1, 5] . As the disease can run an uncommon aggressive course as seen in our case and it's mandatory to define the best therapeutic strategy.
Although local recurrence is common occurring in up to 66.7% of the patients, its potential for distant metastases is negligent (0 -14.3%). According to the very few cases being referred to the literature, lung was the most common site followed by skin [12, 18] .
The majority of patients on surveillance develop metastases within two years from the removal of the primary tumor but a long followup is advised to deal with the risk of delayed metastases even 6 years later as seen in our case [6] .
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Because of its scarcity, there are no series to outline the management of metastatic PCL. Indeed, treatment options in metastatic setting are not dictated by the localization to the skin but by the histological subtype [19] . Classical regimens including doxorubicin, ifosfamide, gemcitabine docetaxel and dacarbazine are used [14] . Although, combination of gemcitabine and docetaxel have shown the best cure rate against metastatic leiomyosarcoma with superior progression-free and overall survival, the high incidence of toxicity was the cause that limited the use of this combination in our palliative setting [20] .
Conclusion
Primary CLM are a diagnostic and therapeutic challenge for 
